Nanostructured lipid carriers for MicroRNA delivery in tumor gene therapy

Wang, Hairong; Liu, Shiming; Li, Jia; Chu, Fengyun; Zhou, Yue; He, Zhixu; Guo, Ming; Chen, Chao; Xu, Lin

doi:10.1186/s12935-018-0596-x

Cited by 49 publications

(40 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, miRNAs can also affect tissue microenvironment through modulation of different type of cells and unlike cancer drugs, miRNAs usually does not have cytotoxicity to normal cells . Thirdly, miRNAs showed reduced immune response and low toxicity when compared with lentivirus‐ or protein‐based gene therapy . Our results demonstrated for the first time that miR‐183 injection treatment may serve as an effective therapeutic treatment for reducing pathologic features of SLE patients.…”

Section: Resultsmentioning

confidence: 79%

MiR‐183 delivery attenuates murine lupus nephritis‐related injuries via targeting mTOR

Liu

et al. 2019

Scand J Immunol

View full text Add to dashboard Cite

MicroRNAs (miRNAs) play a vital role in the occurrence and development of many human diseases, including systemic lupus erythematosus (SLE). SLE is an autoimmune disease characterized by the production of autoantibodies against nuclear antigens and multiorgan involvement. Study of miRNAs involved in SLE provides new insights into the pathogenesis of SLE and might lead to the identification of new therapeutic interventions. The aim of this study was to investigate the effect of miR-183 injection on the progression of SLE by using MRL/lpr mouse model. The expression levels of miR-183 and mTOR mRNA were detected by quantitative real-time PCR assay. The effect of miR-183 on the course of spontaneous disease progression in the MRL/lpr mice was examined by intraperitoneal injection of miR-183 into mice and followed by monitoring lifespan, anti-dsDNA antibody levels, urinary albumin levels, blood urea nitrogen (BUN) levels, and Tregs and Th17 cell population. We found that miR-183 injection resulted in reduction of anti-DNA antibody and immune complex component levels, restoration of Tregs and Th17 cell population and prolongation of survival. Our findings suggest that miR-183 injection may serve as an effective therapeutic treatment for delaying or easing pathologic features of SLE.

show abstract

Section: Resultsmentioning

confidence: 79%

MiR‐183 delivery attenuates murine lupus nephritis‐related injuries via targeting mTOR

Liu

et al. 2019

Scand J Immunol

View full text Add to dashboard Cite

show abstract

“…This may offer a greater opportunity to manage a wider variety of tumors. In fact, it was reported that NLCs can serve as a novel vector in gene therapy for lung cancer [160,161]. In addition, the lack of critical analysis on the safety of NLCs as drug carriers presents another major concern.…”

Section: Future Directionsmentioning

confidence: 99%

Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review

et al. 2020

View full text Add to dashboard Cite

The efficacy of current standard chemotherapy is suboptimal due to the poor solubility and short half-lives of chemotherapeutic agents, as well as their high toxicity and lack of specificity which may result in severe side effects, noncompliance and patient inconvenience. The application of nanotechnology has revolutionized the pharmaceutical industry and attracted increasing attention as a significant means for optimizing the delivery of chemotherapeutic agents and enhancing their efficiency and safety profiles. Nanostructured lipid carriers (NLCs) are lipid-based formulations that have been broadly studied as drug delivery systems. They have a solid matrix at room temperature and are considered superior to many other traditional lipid-based nanocarriers such as nanoemulsions, liposomes and solid lipid nanoparticles (SLNs) due to their enhanced physical stability, improved drug loading capacity, and biocompatibility. This review focuses on the latest advances in the use of NLCs as drug delivery systems and their preparation and characterization techniques with special emphasis on their applications as delivery systems for chemotherapeutic agents and different strategies for their use in tumor targeting.

show abstract

“…miRNAs can easily be transferred to cells and tissues using liposomes [102,125]. Liposomes are composed of cationic lipids structurally characterized by an hydrophobic moiety and a positively charged cationic head; nucleic acids naturally binds to liposomes through their phosphate-generated negative charge [126].…”

Section: Organic Nanoparticles (Nps)mentioning

confidence: 99%

Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes

Grieco

Brusco

Licata

et al. 2019

IJMS

View full text Add to dashboard Cite

Diabetes mellitus is a group of heterogeneous metabolic disorders characterized by chronic hyperglycaemia as a consequence of pancreatic β cell loss and/or dysfunction, also caused by oxidative stress. The molecular mechanisms involved inβ cell dysfunction and in response to oxidative stress are also regulated by microRNAs (miRNAs). miRNAs are a class of negative gene regulators, which modulate pathologic mechanisms occurring in diabetes and its complications. Although several pharmacological therapies specifically targeting miRNAs have already been developed and brought to the clinic, most previous miRNA-based drug delivery methods were unable to target a specific miRNA in a single cell type or tissue, leading to important off-target effects. In order to overcome these issues, aptamers and nanoparticles have been described as non-cytotoxic vehicles for miRNA-based drug delivery. These approaches could represent an innovative way to specifically target and modulate miRNAs involved in oxidative stress in diabetes and its complications. Therefore, the aims of this review are: (i) to report the role of miRNAs involved in oxidative stress in diabetes as promising therapeutic targets; (ii) to shed light onto the new delivery strategies developed to modulate the expression of miRNAs in diseases.

show abstract

Nanostructured lipid carriers for MicroRNA delivery in tumor gene therapy

Cited by 49 publications

References 45 publications

MiR‐183 delivery attenuates murine lupus nephritis‐related injuries via targeting mTOR

MiR‐183 delivery attenuates murine lupus nephritis‐related injuries via targeting mTOR

Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review

Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes

Contact Info

Product

Resources

About